MMED Stock Forecast & Price Target

Minimed Group is attractive fundamentally because its post-split stand-alone structure lets management focus capital and execution on a differentiated diabetes “full-stack” spanning pumps, CGMs, smart pens, and pharmacy fulfillment. The turnaround under Que Dallara has already restored growth, with Q1 revenue of $843M, organic growth of 15.8%, CGM attachment near 69%, and FY27 organic revenue growth guided around 10.5%, while the product cycle—Flex, Fit, Go, Vivera, and next-gen sensors—supports share gains in underpenetrated T1/T2 markets. Financially, the setup implies expanding operating leverage, with adjusted EBITDA modeled to rise from $482M in FY26 to about $852M by FY29 and EPS doubling to $1.56, aided by a clean balance sheet and rising recurring consumables revenue.

Minimed Group is challenged by a likely valuation discount because its forecasted revenue growth is slower than peers, yet it still faces meaningful execution risk as it transitions from Medtronic and absorbs stand-up costs that could limit margin expansion. The company’s dependence on continued new patient starts in Type 1 diabetes, favorable pharmacy-channel economics, and the success of Fit and Vivera makes the outlook vulnerable to competitor launches, cannibalization, and launch delays, while Abbott’s exclusive CGM supply relationship adds concentration risk. Although it is the most profitable of the current pump players and could reach $3.96B of revenue and $801M of EBITDA in CY28E, a negative view persists because that profitability may not be enough to offset slower growth, pricing pressure, and uncertainty around true market expansion.